| Literature DB >> 26910813 |
Kunmu Zheng1,2,3, Xiaoman Dai1,2, Nai'an Xiao2,3, Xilin Wu2, Zhen Wei2, Wenting Fang2, Yuangui Zhu1,2, Jing Zhang4,5, Xiaochun Chen6,7.
Abstract
Alzheimer's disease (AD) is the most common dementia and the trigger of its pathological cascade is widely believed to be the overproduction and accumulation of β-amyloid protein (Aβ) in the affected brain. However, effective AD remedies are still anxiously awaited. Recent evidence suggests that curcumin may be a potential agent for AD treatment. In this study, we used 5×FAD transgenic mice as an AD model to investigate the effects of curcumin on AD. Our results showed that curcumin administration (150 or 300 mg/kg/day, intragastrically, for 60 days) dramatically reduced Aβ production by downregulating BACE1 expression, preventing synaptic degradation, and improving spatial learning and memory impairment of 5×FAD mice. These findings suggest that curcumin is a potential candidate for AD treatment.Entities:
Keywords: Alzheimer’s disease (AD); Curcumin; β-Amyloid protein (Aβ); β-Site amyloid precursor protein cleavage enzyme 1 (BACE1)
Mesh：
Substances：
Year: 2016 PMID： 26910813 DOI： 10.1007/s12035-016-9802-9
Source DB: PubMed Journal: Mol Neurobiol ISSN： 0893-7648 Impact factor: 5.590